Literature DB >> 8759720

Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion.

F D Finkelman1, A Lees, R Birnbaum, W C Gause, S C Morris.   

Abstract

Dendritic cells (DC) are unmatched among APCs in their ability to bind, process, and present Ag. Presentation by such potent APCs, if always immunogenic and never tolerogenic, might stimulate pathogenic autoimmune responses. To determine whether Ag presentation by DC can induce tolerance, mice were injected with a rat IgG2b anti-splenic DC mAb, 33D1, and challenged 13 to 28 days later with a stimulatory rat IgG2b mAb. Injection of mice with 1 ng/100 micrograms of 33D1 rarely induced an anti-rat IgG2b Ab response and, in most mice, induced rat IgG2b-specific T cell and B cell tolerance. Tolerant mice had decreased ability to secrete Ab and make both type 1 and type 2 cytokine mRNA and protein in response to immunization with rat IgG2b. 33D1 was 100- to 1000-fold more potent as a tolerogen than an isotype-matched control rat IgG2b mAb. Injecting mice with aggregated 33D1, 33D1 plus anti-IgD mAb, or 33D1 plus IL-1 induced an IgG1 anti-rat IgG2b Ab response rather than tolerance. IL-1 injected 3 days after 33D1 still induced an Ab response rather than tolerance. Not all anti-DC mAbs are tolerogenic. Injection of a DC-specific hamster anti-CD11c mAb (N418) stimulates an IgG anti-hamster response, and injection of 33D1 plus N418 stimulates both anti-hamster and anti-rat IgG2b responses. These observations indicate that DCs can present Ag in either a tolerogenic or stimulatory manner and suggest that inflammatory stimuli can convert an otherwise tolerogenic signal to a stimulatory signal.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8759720

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

Review 1.  Targeting human dendritic cell subsets for improved vaccines.

Authors:  Hideki Ueno; Eynav Klechevsky; Nathalie Schmitt; Ling Ni; Anne-Laure Flamar; Sandra Zurawski; Gerard Zurawski; Karolina Palucka; Jacques Banchereau; Sangkon Oh
Journal:  Semin Immunol       Date:  2011-01-28       Impact factor: 11.130

2.  Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells.

Authors:  Xin Yu; Wei Xia; Tao Zhang; Hongwei Wang; Yufeng Xie; Jicheng Yang; Jingcheng Miao
Journal:  Int J Hematol       Date:  2010-08-11       Impact factor: 2.490

Review 3.  The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs.

Authors:  Shannon J Turley; Anne L Fletcher; Kutlu G Elpek
Journal:  Nat Rev Immunol       Date:  2010-11-19       Impact factor: 53.106

4.  Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.

Authors:  H Wang; M N Griffiths; D R Burton; P Ghazal
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 5.  Human dendritic cell subsets for vaccination.

Authors:  Peter Dubsky; Hideki Ueno; Bernard Piqueras; John Connolly; Jacques Banchereau; A Karolina Palucka
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

6.  Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.

Authors:  Marianne A Mihalyo; Adam T Hagymasi; Aaron M Slaiby; Erin E Nevius; Adam J Adler
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

7.  Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation.

Authors:  Urban Svajger; Natasa Obermajer; Matjaz Jeras
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

8.  The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.

Authors:  Irina Caminschi; Anna I Proietto; Fatma Ahmet; Susie Kitsoulis; Joo Shin Teh; Jennifer C Y Lo; Alexandra Rizzitelli; Li Wu; David Vremec; Serani L H van Dommelen; Ian K Campbell; Eugene Maraskovsky; Hal Braley; Gayle M Davey; Patricia Mottram; Nicholas van de Velde; Kent Jensen; Andrew M Lew; Mark D Wright; William R Heath; Ken Shortman; Mireille H Lahoud
Journal:  Blood       Date:  2008-07-30       Impact factor: 22.113

9.  Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue.

Authors:  A Porgador; H F Staats; Y Itoh; B L Kelsall
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  Induction of allogeneic mixed chimerism by immature dendritic cells and bone marrow transplantation leads to prolonged tolerance to major histocompatibility complex disparate allografts.

Authors:  Ping Yu; Sidong Xiong; Qiuzao He; Yiwei Chu; Chi Lu; Charmaine A Ramlogan; Jason C Steel
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.